contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


fda-informs-that-the-review-of-arocells-510ksubmission-will-resume-at-the-latest-april-15th-2021

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

IDL Diagnostics är specialiserade inom onkologi och bakteriologi. Bolaget har en bred produktportfölj, och utvecklar, marknadsför och säljer blod-, och urin provtester som används av sjukhus och kliniker. Testerna ämnar ge information för upptäckt av sjukdomar såsom urologiska cancerformer och tyfoidfeber. IDL Diagnostics riktar sig till patientgrupper i olika delar av världen. Huvudkontoret ligger i Stockholm.

IDL Diagnostics

AroCell announced today that the US Food and Drug Administration (FDA) has informed that they will resume the review of AroCells 510(k) submission no later than April 15th 2021.The Food and ...

<div class="mfn-preamble"><p><strong>AroCell announced today that the US Food and Drug Administration (FDA) has informed that they will resume the review of AroCells 510(k) submission no later than April 15th 2021.</strong></p></div><div class="mfn-body"><p>The Food and Drug Administration's Center for Devices and Radiological Health (CDRH) has been actively engaged in responding to the current pandemic caused by a novel coronavirus (SARS-CoV-2) and the associated disease it causes (COVID-19). Due to the on-going national emergency and the large number Emergency Use Authorization (EUA) requests, FDA have received for in vitro diagnostics (IVDs), staff and managers have been reallocated to complete the review of these requests. This has caused a delay in handling of other 510(k) submissions. The review of AroCell´s 510(k) submission will be resumed no later than April 15th 2021.<br/> </p></div><div class="mfn-footer mfn-contacts"><p><strong class="mfn-heading-1">Contacts</strong></p><hr/><p>Anders Hultman, CEO<br/>Phone: +46(0)18 50 30 20<br/>E-mail: <a href="mailto:anders.hultman@arocell.com" target="_blank" rel="nofollow noopener">anders.hultman@arocell.com</a></p></div><div class="mfn-footer mfn-about"><p><strong class="mfn-heading-1">About AroCell</strong></p><hr/><p>AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: <a href="mailto:Certifiedadviser@redeye.se" target="_blank" rel="nofollow noopener">Certifiedadviser@redeye.se</a>, +46 (0)8 121 576 90. For more information; <a href="https://arocell.us12.list-manage.com/track/click?u=afc00720b3f14956d7aa211ee&amp;amp;id=b0c0db8833&amp;amp;e=1eac5f4714" target="_blank" rel="nofollow noopener">www.arocell.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-02-20 13:35 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-pdf"><p><strong class="mfn-heading-1">Attachments</strong></p><hr/><p><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/d2c42e18-c68b-4ae5-bcae-32f7b3337e0f/fda-informs-that-the-review-of-arocells-510-k-submission-will-resume-at-the-latest-april-15th-2021.pdf" target="_blank" rel="nofollow noopener">FDA informs that the review of AroCells 510(k)submission will resume at the latest April 15th 2021</a></p></div>

FDA informs that the review of AroCells 510(k)submission will resume at the latest April 15th 2021